Clinical trials: Patients With Cancer
Indolent Non-follicular, Non-Hodgkin's Lymphoma
A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma
This is a prospective, multicenter phase II trial designed to determine efficacy and safety of a chemoimmunotherapy with the combination of Bendamustine + Rituximab in patients with advanced untreated Indolent non Follicular…
- Trial name
- IIL INFL09 (NCT01929265)
- Testing
- Bendamustine
- Where
- 25 sites in Italy
- Volunteers
- 73 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Metastatic Hepatocellular Carcinoma, Hepatocellular Carcinoma
Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral
Background: Fibrolamellar Hepatocellular Carcinoma (FLC) is a rare liver cancer. It most often occurs in young people who have no history of liver disease. Unresectable FLC most often does not improve with surgery.
- Trial name
- NCT04025567
- Testing
- vancomycin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Web-application, Breast Cancer
Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer
The investigators hypothesize that the implementation of a Web-application in patients initiating adjuvant hormone therapy for breast cancer brings a benefit on treatment adherence and quality of life.
- Conditions
- Web-application, Breast Cancer, Hormono Therapy
- Trial name
- WEBAPPAC (NCT04554927)
- Testing
- WEB-Application, Standard accompaniment
- Where
- France
- Volunteers
- 438 people
- Sponsor
- Centre Francois Baclesse
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer
This trial studies magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging in predictive treatment response in patients with stage IB-IVA cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Cervical Undifferentiated Carcinoma
- Trial name
- NCT01992861
- Testing
- Computed Tomography, Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 51 people
- Sponsor
- University of Washington
Metastatic Breast Cancer, Liver Metastases
Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer
This is a phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tumour in combination with trastuzumab (Herceptin®)…
- Trial name
- NCT01387373
- Testing
- oxaliplatin, capecitabine, trastuzumab
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- Dorte Nielsen
Graft Versus Host Disease, Hematologic Malignancy
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-CSH). Recently, in the context of semi-identical (=haploidentical) HLA donors, but also of compatible HLA…
- Trial name
- CY-MET-RIC (NCT06252870)
- Testing
- Methotrexate, Post-Transplant Cyclophosphamide, Fludarabine
- Where
- 3 sites in France
- Volunteers
- 82 people
- Sponsor
- Nantes University Hospital
Lung Cancer, Sarcopenia
Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC
This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin/Paclitaxel in advanced NSCLC.
- Conditions
- Lung Cancer, Sarcopenia, Toxicity
- Trial name
- NCT02734069
- Testing
- Carboplatin
- Where
- Mexico
- Volunteers
- 132 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
High-Grade Glioma
Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent temozolomide based on O6-Methylguanine-DNA…
- Trial name
- NCT06829173
- Testing
- XRD-0394, Radiation Therapy, Surgical Resection
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- NYU Langone Health
Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC
Head and Neck Squamous Cell Carcinoma (HNSCC) is the most common malignant tumor of the head and neck, accounting for 90% of head and neck malignancies, and 16% to 40% of systemic malignancies.
- Trial name
- NCT04947241
- Testing
- PD-1 inhibitor+ Gemcitabine + Cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Non-small Cell Lung Cancer
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
The purpose of this Phase I study is to test the safety of combining afatinib with standard chemotherapy and radiation. The drug afatinib will be given before the chemotherapy and radiation therapy to shrink the tumor and…
- Trial name
- NCT01836341
- Testing
- Afatinib, Cisplatin, Carboplatin
- Sponsor
- Memorial Sloan Kettering Cancer Center
HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IIIA Breast Cancer
- Trial name
- NCT00436254
- Testing
- pNGVL3-hICD vaccine, sargramostim, flow cytometry
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Washington
Fruquintinib, S-1
Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC
Based on the FRECO-2 study, Fruquintinib has become one of the standard third-line treatments for advanced colorectal cancer; however, its objective response rate (ORR) remains low.
- Conditions
- Fruquintinib, S-1, Raltitrexed
- Trial name
- NCT06427005
- Testing
- Fruquintinib, S-1, raltitrexed
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Meng Qiu
Adult Solid Neoplasm
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
This phase I trial studies the side effects and best dose of tivantinib when given in combination with temsirolimus in treating patients with solid tumors that have spread to other parts of the body or cannot be removed by…
- Trial name
- NCT01625156
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancies
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with…
- Trial name
- NCT04588922
- Testing
- SLS009, venetoclax, azacitidine
- Where
- 32 sites in United States, China
- Volunteers
- 160 people
- Sponsor
- Sellas Life Sciences Group
Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas.
- Conditions
- Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- PXD101-CLN-6 (NCT00274651)
- Testing
- belinostat
- Where
- 15 sites in United States, France and 3 more
- Volunteers
- 53 people
- Sponsor
- Valerio Therapeutics
Leukemia, Cancer
WT1 for the Detection of Minimal Residual Disease
The purpose of this study is to determine if WT1 is an adequate measurement of minimal residual disease in leukemic patients.
- Trial name
- NCT00179829
- Testing
- WT 1 Testing
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with surgery may kill more tumor cells.
- Trial name
- NCT00003231
- Testing
- cisplatin, docetaxel, surgical procedure
- Where
- 9 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- Swiss Cancer Institute
Solid Tumor
A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment and nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-B16D1 in…
- Trial name
- NCT06475131
- Testing
- BL-B16D1
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Radiation Toxicity, Chemotherapeutic Toxicity
Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025
The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms, who have been referred to the HUGCDN Chronic Pain Unit for adjuvant palliative treatment with…
- Conditions
- Radiation Toxicity, Chemotherapeutic Toxicity, Chemotherapy-induced Peripheral Neuropathy, Delayed Wound Healing
- Trial name
- EPOOzo (NCT05417737)
- Testing
- Ozone therapy
- Where
- Spain
- Volunteers
- 105 people
- Sponsor
- Bernardino Clavo, MD, PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.